Intensity Therapeutics

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immunotherapy-based approach to treating solid tumor cancers. We utilize our DfuseRxSM technology platform to create novel drug formulations that, after direct injection, rapidly disperse throughout the tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors.